Clinical trials: Atheroscleroses
- Condition Atheroscleroses
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy Volunteers
Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884
A Phase 1, single dose study with 4 cohorts of ascending doses and an optional Japanese cohort designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of MEDI5884 in healthy volunteers
- Trial name
- NCT03001297
- Testing
- MEDI5884 Dose 1, MEDI5884 Dose 2, MEDI5884 Dose 3
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Critical Limb Ischemia
Validation of OxyVu for Assessing Level of Amputation With Comparison to Other Modalities
Correlation of(OxyVu) values to to ABI, TBP, and TCOM in patients scheduled for foot level amputation because of critical limb ischemia, infection, or tissue necrosis.
- Trial name
- LOA (NCT00767923)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- HyperMed
Healthy Subjects, Atherosclerosis
Effect Of Rilapladib (SB-659032) On Platelet Aggregation
The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.
- Trial name
- NCT00387257
- Testing
- Rilapladib (SB-659032)
- Where
- Australia
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atherosclerosis
Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart
This is a study to assess the effects of darapladib on the cardiac conduction of the heart as compared to placebo and moxifloxacin. This a four period crossover design with each period lasting about 10 days.
- Trial name
- NCT00411073
- Testing
- Darapladib
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2, Diabetic Foot
Non-invasive Imaging for In-vivo Quantification of Skin Composition and Structure
The goal of this clinical investigation is to explore a non-invasive technology for measuring the microcirculatory structure, composition and function in patients from a primary care population. The main aims are: 1.
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Foot, Peripheral Arterial Disease, Skin Cancer
- Trial name
- Spectrum1 (NCT06976073)
- Where
- 3 sites in Sweden
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- HJN Sverige AB/Neko Health
Atherosclerosis
Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects
The primary purpose of this study is to evaluate the safety and tolerability of multiple oral doses of BMS-779788 in healthy subjects
- Trial name
- NCT00836602
- Testing
- BMS-779788
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Disease (CAD), Heart Disease
Using CTA Measures to Define Cardiac Risk In NFL Alumni
The GAMEFILM Registry is a post-market, multi-center, data collection study assessing the presence of CAD in NFL alumni.
- Conditions
- Coronary Artery Disease (CAD), Heart Disease, Coronary Atherosclerosis
- Trial name
- GAMEFILM (NCT06831409)
- Testing
- Coronary computed tomography angiography
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- HeartFlow, Inc.
Cardiovascular Risk
Precision Study of CLAiR AI Software
This multi-site precision study evaluated the performance and reproducibility of the CLAiR artificial intelligence (AI) software in identifying elevated risk of atherosclerotic cardiovascular disease (ASCVD) from retinal fundus…
- Trial name
- NCT07747233
- Testing
- CLAiR Artificial Intelligence Software
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Toku Eyes Ltd
Peripheral Arterial Disease
Validation of a Novel Oscillometric-Based Algorithm for Determination of the Ankle-Brachial Index
Peripheral arterial disease (PAD) is a highly prevalent medical condition. Patients with PAD are usually diagnosed on the basis of the ankle-brachial index.
- Trial name
- NCT01165437
- Testing
- Blood Pressure Measurement
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Summit Doppler Systems, Inc.
Peripheral Arterial Occlusive Disease, Critical Limb Ischemia
Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)
The goal of this Phase 0 clinical trial is to evaluate safety and biodistribution of [89Zr]Zr-DFO-APAC in patients with peripheral arterial occlusive disease / critical limb ischemia (PAOD/CLI) and healthy volunteers.
- Trial name
- CHASE (NCT06204237)
- Testing
- [89Zr]Zr-DFO-APAC, PET/CT scan
- Where
- Netherlands
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Aplagon Oy
Peripheral Arterial Disease
Using SnapshotNIR With Provocative Leg Maneuver for PAD Assessment
The objective of this trial is to determine if Near-infrared spectroscopy (NIRS) can accurately evaluate the degree of Peripheral Arterial Disease (PAD) during a Provocative Elevation Maneuver of the Lower Extremity (PEMLE) test…
- Trial name
- NCT06237621
- Testing
- SnapshotNIR imaging
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Kent Imaging Inc
Atherosclerosis
SB-659032 Platelet Aggregation Study
This study is designed to assess whether inhibition of plasma Lp-PLA2 activity impacts platelet function as assessed by ex vivo platelet aggregation tests and in vivo plasma biomarkers.
- Trial name
- NCT01745458
- Testing
- SB-659032
- Where
- Australia
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atherosclerosis
Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects
This study will determine the effect of single and repeat administration of darapladib, a novel, selective, orally active inhibitor of lipoprotein associated phospholipase A2 (Lp-PLA2) currently under clinical development on the…
- Trial name
- NCT01873339
- Testing
- Darapladib, Midazolam
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atherosclerosis
An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism
The purpose of this study is to validate novel assays for serum biomarkers of lipid metabolism (PCSK9 and LDL receptor) and to obtain information about how these biomarkers differ in subjects with normal or high cholesterol levels
- Trial name
- NCT00847782
- Testing
- Blood draw
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Atherosclerosis
Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects
The purpose of this study is to determine any differences in pharmacokinetic parameters of darapladib when dosed to people with moderate liver disease as compared to when dosed in normal healthy volunteers.
- Trial name
- NCT01154114
- Testing
- darapladib
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Peripheral Artery Disease
FlowMet-R Blood Flow Measurement for the Diagnosis of Peripheral Artery Disease and Critical Limb Ischemia
Non-randomized, multi-center, longitudinal study of healthy subjects and subjects with PAD who are scheduled for ABI, TBI, and either Duplex Ultrasound or Angiographic assessments in a vascular clinic.
- Trial name
- NCT04120610
- Testing
- FlowMet-R, ABI, TBI
- Where
- 5 sites in United States
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Medtronic Endovascular
Hypercholesterolemia
Safety Study of Bile Acid to Treat Hypercholesteremia
Preclinical data support the hypothesis that the administration of AHRO-001 reduces LDL cholesterol levels, improves HDL function, and finally, decreases atheromatous plaque burden.
- Trial name
- NCT01931241
- Testing
- AHRO-001
- Where
- Russia
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AtheroNova Inc.
Intermittent Claudication
BE Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered once daily and the reference formulation of…
- Trial name
- NCT05466734
- Testing
- Cilostazol Tablet 100 mg, PMR Tablet 135 mg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Healthy Subjects, Dyslipidaemias
Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.
The rationale for this study is to determine whether GW856553 (7.5mg BD for 28 days) has an effect on endothelial function in dyslipidaemic subjects as assessed by venous occlusion plethysmography using brachial artery…
- Conditions
- Healthy Subjects, Dyslipidaemias, Dyslipidaemia
- Trial name
- NCT00474864
- Testing
- GW856553
- Where
- 3 sites in United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atherosclerosis
Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis
This is a trial of Ateronon in Patients with Coronary Disease to Evaluate its Effectiveness in Assessing the Risk Factors of Atherosclerosis.
- Trial name
- NCT01287182
- Testing
- Ateronon
- Where
- Lebanon
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Omicron Pharmaceuticals